Meghan Menges
A5078406715- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- RNA Interference and Gene Delivery
- Biosimilars and Bioanalytical Methods
- vaccines and immunoinformatics approaches
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Viral Infectious Diseases and Gene Expression in Insects
- Protein Degradation and Inhibitors
- Neutropenia and Cancer Infections
- Gut microbiota and health
- Hematological disorders and diagnostics
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
- Nanowire Synthesis and Applications
- Autophagy in Disease and Therapy
- Reproductive System and Pregnancy
- Mycobacterium research and diagnosis
- Hepatitis B Virus Studies
- Cancer Mechanisms and Therapy
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Pneumonia and Respiratory Infections
Moffitt Cancer Center
2015-2025
University of South Florida
2022-2023
A subset of patients with diffuse large B-cell lymphoma (DLBCL) treated CD19 chimeric antigen receptor (CAR) T-cell therapy have poor clinical outcomes. We report serum proteins associated severe immune-mediated toxicities and inferior responses in 146 DLBCL axicabtagene ciloleucel. develop a simple stratification based on pre-lymphodepletion C reactive protein (CRP) ferritin to classify into low-, intermediate-, high-risk groups. observe that the category were more likely grade ≥3 had...
Increasing evidence suggests that the gut microbiome may influence responses and toxicities associated with chimeric antigen receptor (CAR) therapy. We conducted whole-genome shotgun sequencing on stool samples (n=117) collected at various times from multiple myeloma patients (n=33) undergoing idecabtagene vicleucel (ide-cel) anti-B cell maturation CAR-T observed a significant decrease in bacterial diversity post-ide-cel infusion, along differences composition linked to therapy response...
CD19 targeted chimeric antigen receptor-modified T cell therapy (CAR-T) leads to B aplasia and low serum immunoglobulin levels. Long-lived CD19-negative plasma cells may persist through the generate antibodies. There is a paucity of data describing how CAR-T impacts persistence antibodies against vaccine-related antigens degree which recipients respond vaccines. We characterized effect on pneumococcal G (IgG) titers determine whether conjugate vaccine (PCV13) administered after develops...
Abstract Purpose: We investigated whether a dendritic cell (DC) vaccine transduced with an adenoviral vector encoded full-length survivin (Ad-S), mutations neutralizing its antiapoptotic function, could safely generate immune response and deepen clinical responses when administered before after autologous stem transplant (ASCT) for multiple myeloma. Patients Methods: This phase I first-in-human trial (NCT02851056) evaluated the safety of DC:Ad-S in newly diagnosed myeloma not having achieved...
Acute graft-versus-host disease (GVHD) is an important cause of morbidity and death after allogeneic hematopoietic cell transplantation (HCT). We identify a new approach to prevent GVHD that impairs monocyte-derived dendritic (moDC) alloactivation T cells, yet preserves graft-versus-leukemia (GVL). Exceeding endoplasmic reticulum (ER) capacity results in spliced form X-box binding protein-1 (XBP-1s). XBP-1s mediates ER stress inflammatory responses. demonstrate siRNA targeting XBP-1 moDCs...
Chimeric antigen receptor (CAR)-T cells are engineered to identify and eliminate expressing a target antigen. Current manufacturing protocols vary between commercial CAR-T cell products warranting an assessment of these methods determine which approach optimally balances successful capacity product efficacy. One difference is whether T engineering begins with fresh (unfrozen) patient or that have been cryopreserved prior manufacture. Starting frozen PBMC material allows for greater...
Survivin is a small protein inhibitor of apoptosis and tumor associated antigen. expression in multiple myeloma with poor prognosis, disease progression, drug resistance. The CD4+ response against survivin remains uncharacterized.In order to better understand the anti-tumor immune survivin, optimize vaccination strategies, we characterized spontaneous CD4+CD25- T cell healthy donors patients using derived peptide pools.Healthy patients' cells exhibited proliferative IFN-gamma peptides loaded...
<p>Table S3 shows the Multivariable Cox Regression analysis of overall (A) and progression free survival (B) using CRP Ferritin risk categories</p>
<p>Figure S1 shows the serum markers associated with severe CRS and ICANS</p>
<p>Table S2 shows Multivariable analysis of grade >2 ICANS across the three risk groups.</p>